Sanofi and Novavax Forge Major Alliance, Boosting Novavax's Market Position

The $1.2 billion deal includes co-commercialization of COVID-19 vaccines and development of new flu-COVID combo vaccines, marking a significant turnaround for Novavax.

Novavax's stock surged following the announcement, reflecting renewed investor confidence in its future.
Sanofi's investment includes a $500 million upfront payment and potential future milestones totaling up to $700 million.
The partnership aims to enhance global access to non-mRNA COVID-19 vaccines starting in 2025.
Novavax will receive double-digit percentage royalties on vaccine sales by Sanofi, strengthening its financial base.
The deal also entails Sanofi taking a minority stake in Novavax, further cementing the strategic partnership.